CUR - Neuralstem, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.7200
+0.0300 (+1.78%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close1.6900
Open1.6900
Bid1.6000 x 800
Ask0.0000 x 800
Day's Range1.5700 - 1.8000
52 Week Range1.5000 - 24.4000
Volume114,961
Avg. Volume99,742
Market Cap3.612M
Beta (3Y Monthly)2.73
PE Ratio (TTM)N/A
EPS (TTM)-7.8300
Earnings DateAug 9, 2018 - Aug 10, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est26.00
Trade prices are not sourced from all markets
  • PR Newswire

    Neuralstem Reports Second Quarter 2019 Fiscal Results

    GERMANTOWN, Md. , Aug. 14, 2019 /PRNewswire/ -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell and small ...

  • Germantown biopharma regains compliance with Nasdaq
    American City Business Journals

    Germantown biopharma regains compliance with Nasdaq

    The Nasdaq Hearings Panel concluded Neuralstem showed compliance by meeting the minimum $1 bid price requirement.

  • PR Newswire

    Neuralstem Announces Nasdaq Hearings Panel Grants Request For Continued Listing

    GERMANTOWN, Md., Aug. 7, 2019 /PRNewswire/ -- Neuralstem, Inc. (CUR) ("Neuralstem" or the  Company") today announced that on August 6, 2019, it received a letter from the Office of General Counsel of The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that the Nasdaq Hearings Panel (the "Panel") has granted the Company's request for continued listing of the Company's stock on the Nasdaq Stock Market.

  • PR Newswire

    Neuralstem Closes $7.5 Million Underwritten Public Offering

    GERMANTOWN, Md., July 31, 2019 /PRNewswire/ -- Neuralstem, Inc. (CUR) ("Neuralstem" or the "Company") today announced the closing of its underwritten public offering of an aggregate of 2,777,777 units at a public offering price of $2.70 per unit resulting in  gross proceeds of approximately $7,500,000, before deducting discount,  commissions and estimated offering expenses. Each unit issued was comprised of one share of common stock (or common stock equivalent), one short-term warrant to purchase one share of common stock and one long-term warrant to purchase one share of common stock (collectively, a "warrant combination").

  • PR Newswire

    Neuralstem Announces Pricing of $7.5 Million Underwritten Public Offering

    GERMANTOWN, Md., July 25, 2019 /PRNewswire/ -- Neuralstem, Inc. (CUR) ("Neuralstem" or the "Company") today announced the pricing of its underwritten public offering of an aggregate of 2,777,777 units at a public offering price of $2.70 per unit for gross proceeds of approximately $7,500,000, before deducting discount and commissions and estimated offering expenses. Each unit is comprised of one share of common stock (or common stock equivalent), one short-term warrant to purchase one share of common stock and one long-term warrant to purchase one share of common stock (collectively, a "warrant combination").

  • PR Newswire

    Neuralstem Appoints Mary Ann Gray, Ph.D., to Board of Directors

    GERMANTOWN, Md., July 18, 2019 /PRNewswire/ -- Neuralstem, Inc. (CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell and small molecule technologies, announced that Mary Ann Gray, Ph.D. has been appointed to the Company's Board of Directors. "We are pleased to welcome Mary Ann to our board, her expertise and leadership pharmaceutical and biotech industry will be a great asset to Neuralstem," said Dr. Ken Carter, Executive Chairman of the Board. "Both Dr. Gray's substantial background in pharmacology and finance—as well as—her dedication to developing new treatments, reflects our shared commitment here at Neuralstem to improve patient outcomes.

  • PR Newswire

    Neuralstem Announces a 1-for-20 Reverse Stock Split

    GERMANTOWN, Md., July 16, 2019 /PRNewswire/ -- Neuralstem, Inc. (CUR), a biopharmaceutical company focused on developing novel treatments for nervous system diseases, today announced a reverse stock split of its shares of common stock at a ratio of 1-for-20. The reverse stock split will become effective on Wednesday, July 17, 2019 after market close and shares of Neuralstem Inc. common stock will trade on a post-split basis on the Nasdaq Capital Market under the Company's existing trading symbol, "CUR," at the market open on Thursday, July 18, 2019.

  • Germantown stem cell therapy company proposes $7M offering amid delisting threat
    American City Business Journals

    Germantown stem cell therapy company proposes $7M offering amid delisting threat

    The company’s future on the Nasdaq hangs in the balance, as its share price continues to sit below a buck in the wake of a delisting threat from the exchange.

  • PR Newswire

    Neuralstem Announces Publication of Results from Phase 1 Clinical Trial Evaluating Human Neural Stem Cells in Chronic Stroke Patients

    GERMANTOWN, Md., July 1, 2019 /PRNewswire/ -- Neuralstem, Inc. (CUR), a biopharmaceutical company focused on developing novel treatments for nervous system diseases, announced the publication of a manuscript in Stem Cells Translational Medicine describing the results of an open label Phase 1 clinical trial evaluating the feasibility and safety of transplantation of its lead stem cell asset, NSI-566, for the treatment of motor deficits due to ischemic stroke. The manuscript, entitled 'Stable Intracerebral Transplantation of Neural Stem Cells for the Treatment of Paralysis Due to Ischemic Stroke,' summarizes the results of an open label trial performed at BaYi Brain Hospital in Beijing, China, with Principal Investigator Professor Xu Ruxiang.

  • Germantown biopharma stock on the brink of delisting
    American City Business Journals

    Germantown biopharma stock on the brink of delisting

    Germantown-based Neuralstem Inc. (NASDAQ: CUR) has received notice that it could be delisted from the Nasdaq after failing to elevate its stock price consistently above $1 over the past six months. The stem cell therapy company received a letter May 29 that it will be delisted from the exchange, scheduled to take effect June 7, unless it requests a hearing by Wednesday afternoon before the Nasdaq Hearings Panel — which, the company reported in public filings, it intends to do. “At the hearing, the Company will present its plan to regain compliance with all applicable requirements for continued listing on Nasdaq, including the $1.00 bid price requirement, and request an extension within which to do so,” Neuralstem wrote in its filings.

  • PR Newswire

    Neuralstem Announces Issuance of New Patent Covering Broad Therapeutic Use of Neural Stem Cells

    GERMANTOWN, Md. , May 16, 2019 /PRNewswire/ -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced the expansion of their ...

  • PR Newswire

    Neuralstem Reports First Quarter 2019 Fiscal Results

    - Kenneth C. Carter, PhD appointed Executive Chairman - Strategic initiative to expand pipeline announced GERMANTOWN, Md. , May 14, 2019 /PRNewswire/ -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical ...

  • PR Newswire

    Neuralstem Appoints David J. Mazzo, Ph.D., to Board of Directors

    GERMANTOWN, Md., May 6, 2019 /PRNewswire/ -- Neuralstem, Inc. (CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell and small molecule technologies, announced that David J. Mazzo, Ph.D. has been appointed to the Company's Board of Directors to be effective June 12, 2019. Dr. Mazzo will replace Stanley Westreich, who is retiring on the effective date. "Dr. Mazzo is a seasoned executive in the biopharma space and brings Neuralstem significant value gained over his 30 years in the pharmaceutical and biotech industries," said Dr. Ken Carter, Executive Chairman of the Board.

  • Some Neuralstem (NASDAQ:CUR) Shareholders Have Copped A 99% Share Price Wipe Out
    Simply Wall St.

    Some Neuralstem (NASDAQ:CUR) Shareholders Have Copped A 99% Share Price Wipe Out

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! While not a mind-blowing move, it is good to see that the Neuralstem, Inc. (NASDAQ:CUR) share pric...

  • GlobeNewswire

    Neuralstem Reports Year End 2018 Fiscal Results

    GERMANTOWN, Md., March 22, 2019 -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem.

  • PR Newswire

    Neuralstem to Expand Pipeline as Part of Aggressive Growth Effort

    Neuralstem Engages Strategic Advisors to Evaluate Dozens of New Technologies GERMANTOWN, Md. , Feb. 7, 2019 /PRNewswire/ --  Neuralstem, Inc. (NASDAQ: CUR), a biopharmaceutical company focused on the development ...

  • GlobeNewswire

    Neuralstem Appoints Ken Carter, Ph.D., as Executive Chairman of the Board

    Neuralstem, Inc. (CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell and small molecule technologies, appointed Kenneth C. Carter, Ph.D., as the Company’s Executive Chairman of the Board to be effective on January 1, 2019. Dr. Carter will replace interim CEO, Jim Scully, who will be stepping down. “Dr. Carter brings a wealth of drug development expertise and executive leadership having led both private and public biotechnology companies.

  • Germantown biotech faces stock delisting threat
    American City Business Journals

    Germantown biotech faces stock delisting threat

    Germantown-based Neuralstem Inc. has been put on notice that its stock could be delisted from the Nasdaq if the company can’t raise its share price above $1 continually within the next six months. The stem cell therapy company said it intends to continue actively monitoring its common stock price and will consider options to boost its value. To return to compliance, Neuralstem stock must close at or above $1 per share for at least 10 consecutive days, though the company could file for an extension or appeal.

  • How Financially Strong Is Neuralstem Inc (NASDAQ:CUR)?
    Simply Wall St.

    How Financially Strong Is Neuralstem Inc (NASDAQ:CUR)?

    Neuralstem Inc (NASDAQ:CUR), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is CUR will Read More...

  • GlobeNewswire

    Market Trends Toward New Normal in Neuralstem, Industrial Services of America, Gulf Resources, Natural Alternatives International, Lifevantage, and Lonestar Resources US — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, Nov. 19, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire

    Neuralstem Reports Third Quarter 2018 Financial Results and Provides Business Update

    - NSI-189 Received Orphan Designation for Treatment of Angelman Syndrome - - Initiated Phase 2 Clinical Trial of NSI-566 for Treatment of Chronic Stroke - -.